RG6662

Gene therapy / editing

Mechanism not established

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

—no registered trials

Evidence outlook

No clinical trials on ClinicalTrials.gov

No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.

No registered studies found. Not yet ingested, or none registered.

Competitive landscape

This drug's own stage for Huntington's Disease: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
RG6662: this drugStage not on recordGene therapy / editing—not yet gradedNo reviewed efficacy summary in this indication
Valbenazine (Ingrezza)ApprovedSmall moleculevesicular monoamine transporter 2 (VMAT2)Partial signal
NCT04102579: Primary endpoint, change in UHDRS Total Maximal Chorea score (average of weeks 10 and 12): -4.6 with valbenazine vs -1.4 with placebo, treatment effect -3.2 units, p<0.0001 (INGREZZA label, KINECT-HD).
VotoplamPhase 3Small moleculeHuntingtin (HTT)not yet gradedNo reviewed efficacy summary in this indication
TanruprubartPhase 2Monoclonal antibodyComplement C1qnot yet gradedNo reviewed efficacy summary in this indication
Ifezuntirgene InilparvovecPhase 1/2Gene therapy / editingHuntingtin (HTT) genenot yet gradedNo reviewed efficacy summary in this indication
WVE-003Phase 1/2RNA / oligonucleotideHuntingtin (HTT)Weak signal
NCT05032196: Registered primary was the proportion of patients with study-drug-related TEAEs, with no formal test: single doses 30 mg 1/13, 60 mg 3/10, 90 mg 3/8 vs pooled placebo 2/16; multidose 30 mg 8/16 vs placebo 0/7 (CT.gov posted results).
BrezosiranPhase 1RNA / oligonucleotideHuntingtin (HTT)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.